CSTONE PHARMA-B (02616) CEO and Executive Director Yang Jianxin and senior management added purchasing 1 million shares.

CSTONE PHARMA-B(02616) announced that the company has been informed by Yang Jianxin and senior management that they collectively purchased 1 million shares of the company's stock (stock purchase) with personal funds on the open market from October 20 to October 22, 2025, with Yang Jianxin purchasing 700,000 shares. This recent purchase continues Yang Jianxin's consistent commitment. Since becoming CEO in August 2022, Yang Jianxin has purchased a total of 11.501 million shares. After this stock purchase, Yang Jianxin holds approximately 4.81% of the company's total issued share capital as of the date of this announcement. Yang Jianxin and senior management stated that they are confident in the long-term investment value and future growth prospects of the company, and increasing their holdings in the company represents their belief that the company has the ability to maintain steady operations and rapid growth in the future. They also do not rule out the possibility of further increasing their holdings in the company at the appropriate time. The board of directors believes that Yang Jianxin and senior management increasing their holdings in the company reflects their long-term commitment to the company and confidence in its future business prospects.